Gilead Sciences said on Monday its experimental HIV treatment met the main goal in a late-stage trial. The treatment regimen ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are ...
Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...
Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a ...
BitMine Immersion Technologies ("BitMine" or the "Company") a Bitcoin and Ethereum Network Company with a focus on the accumulation of crypto for long term investment, today announced BitMine crypto + ...
The team at Further Financial Group, led by partners Michael Broughton, John Fidder, and Matt Wissman, helps clients prepare to meet their future financial goals through knowledgeable advice, ...
RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...
The deal revolves around a drug Sobi claimed could become the “therapy of choice” for people whose gout symptoms persist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback